VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (8341)	10/17/2000 12:15:35 AM
From: RCMac	Read Replies (2) of 9719

>> The CEO of Corixa has a reputation as a ruthless deal maker. I think he got a bargain in CLTR. Isn't this the same guy who used to be the CEO of Immunex? << Yes. See the January TWST interview with him, linked in post 8336. CRXA's CFO on CNBC at about 5:20 made the point that the FDA's date for acceptance or rejection of the Bexxar BLA is before the date for CRXA and CLTR shareholder approval, so that the CRXA shareholders could reject the deal if the FDA again rejects the BLA. In other words, CLTR sold CRXA an option to buy CLTR. Ruthless indeed. -- RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next